Dashboard
Manage Tickers

RYTM


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

rhythm-says-european-medicines-agencys-chmp-adopted-positive-opinion-recommending-marketing-authorization-for-imcivree-european-commission-decision-anticipated-in-h2-of-2024
Rhythm Says European Medicines Agency's CH...
06/28/2024 12:02:51

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...

rhythm-pharmaceuticals-grants-inducement-equity-covering-56080-shares-to-ten-new-employees
Rhythm Pharmaceuticals Grants Inducement E...
06/11/2024 20:02:03

Including Options For 9,230 Shares And RSUs For 46,850 Shares

rhythm-pharmaceuticals-presents-first-patient-and-caregiver-reported-experiences-from-phase-2-trial-of-setmelanotide-in-hypothalamic-obesity-at-endo-2024
Rhythm Pharmaceuticals Presents First Pati...
06/03/2024 20:04:43

- Participants from the completed Phase 2 hypothalamic obesity trial reported positive changes in sleep, energy levels during s...

rhythm-pharmaceuticals-announced-that-the-national-institute-for-health-and-care-excellence-issued-guidance-that-recommends-imcivree-setmelanotide-as-an-option-for-treatment-of-obesity-and-hyperphagia-in-patients-with-bardet-biedl-syndrome
Rhythm Pharmaceuticals Announced That The ...
05/22/2024 08:02:12

canaccord-genuity-maintains-buy-on-rhythm-pharmaceuticals-lowers-price-target-to-79
Canaccord Genuity Maintains Buy on Rhythm ...
05/08/2024 16:55:55

Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target...

b-of-a-securities-downgrades-rhythm-pharmaceuticals-to-neutral-lowers-price-target-to-42
B of A Securities Downgrades Rhythm Pharma...
05/08/2024 10:17:30

B of A Securities analyst Tazeen Ahmad downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) from Buy to Neutral and lowers the pr...

needham-maintains-buy-on-rhythm-pharmaceuticals-lowers-price-target-to-46
Needham Maintains Buy on Rhythm Pharmaceut...
05/07/2024 18:11:57

Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $...

rhythm-pharmaceuticals-q1-2024-gaap-eps-235-misses-212-estimate-sales-25967m-miss-26896m-estimate
Rhythm Pharmaceuticals Q1 2024 GAAP EPS $(...
05/07/2024 11:02:02

rhythm-pharmaceuticals-presents-data-from-phase-3-pediatrics-trial-at-pediatric-endocrine-society-annual-meeting
Rhythm Pharmaceuticals Presents Data From ...
05/06/2024 12:15:08

-- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z s...

rhythm-pharmaceuticals-announces-publication-of-results-from-phase-2-study-of-setmelanotide-for-the-treatment-of-hypothalamic-obesity-in-the-lancet-diabetes--endocrinology
Rhythm Pharmaceuticals Announces Publicati...
04/29/2024 22:49:41

- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks...

analyst-expectations-for-rhythm-pharmaceuticalss-future
Analyst Expectations For Rhythm Pharmaceut...
04/26/2024 13:01:18

needham-reiterates-buy-on-rhythm-pharmaceuticals-maintains-50-price-target
Needham Reiterates Buy on Rhythm Pharmaceu...
04/26/2024 10:39:34

Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $50 price target.

jim-cramer-is-willing-to-let-this-pharma-stock-catch-fire-advises-not-to-sell-mckesson
Jim Cramer Is 'Willing To Let This Pharma ...
04/19/2024 12:46:13

The "Mad Money" host recommended buying some Marvell Technology, and then wait until under $60 to buy the rest.

wells-fargo-maintains-overweight-on-rhythm-pharmaceuticals-lowers-price-target-to-52
Wells Fargo Maintains Overweight on Rhythm...
04/18/2024 12:59:42

Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and lowers the price targ...

5-analysts-assess-rhythm-pharmaceuticals-what-you-need-to-know
5 Analysts Assess Rhythm Pharmaceuticals: ...
04/10/2024 16:00:49

needham-reiterates-buy-on-rhythm-pharmaceuticals-maintains-50-price-target
Needham Reiterates Buy on Rhythm Pharmaceu...
04/10/2024 10:26:02

Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $50 price target.

rhythm-pharmaceuticals-announces-first-patient-dosed-in-phase-1-trial-evaluating-rm-718
Rhythm Pharmaceuticals Announces First Pat...
03/25/2024 12:04:49

- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce b...

analyst-expectations-for-rhythm-pharmaceuticalss-future
Analyst Expectations For Rhythm Pharmaceut...
02/22/2024 18:00:42

needham-reiterates-buy-on-rhythm-pharmaceuticals-maintains-50-price-target
Needham Reiterates Buy on Rhythm Pharmaceu...
02/22/2024 17:25:18

Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $50 price target.

rhythm-pharmaceuticals-announced-plans-to-add-a-cohort-of-patients-with-hypothalamic-obesity-in-japan-to-its-ongoing-global-phase-3-clinical-trial-of-setmelanotide-with-dosing-expected-to-begin-in-the-third-quarter-of-2024
Rhythm Pharmaceuticals Announced Plans To ...
02/22/2024 12:09:24

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)